Advertisement
Canadian Journal of Cardiology

Erratum to “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” [Can J Cardiol (2022):1153-1167].

    Open AccessPublished:October 25, 2022DOI:https://doi.org/10.1016/j.cjca.2022.10.008
        In the article, “2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults” by Mancini et al., published in the August 2022 issue (Can J Cardiol 2022;38:1153-67), an author was accidentally omitted from the author list. Jonathan Y. Gabor, MD, should have been listed as the second author in the Secondary Panel section. Dr Gabor is affiliated with the Department of Cardiology, Selkirk Regional Health Centre, Selkirk, Manitoba, Canada. This information has been corrected in the online version of the article.

        Linked Article